Somewhat Favorable News Coverage Somewhat Unlikely to Affect Orexigen Therapeutics (OREX) Share Price

Press coverage about Orexigen Therapeutics (NASDAQ:OREX) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.3209361999831 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Orexigen Therapeutics (OREX) traded down $0.03 during trading on Wednesday, hitting $1.17. The company had a trading volume of 133,000 shares, compared to its average volume of 313,779. The company has a quick ratio of 1.71, a current ratio of 2.00 and a debt-to-equity ratio of -2.75. Orexigen Therapeutics has a one year low of $1.15 and a one year high of $5.70.

Orexigen Therapeutics (NASDAQ:OREX) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.78. The company had revenue of $18.90 million during the quarter, compared to the consensus estimate of $24.20 million. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 192.65%. The firm’s revenue for the quarter was up 170.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.12 earnings per share. equities analysts predict that Orexigen Therapeutics will post -10.08 earnings per share for the current fiscal year.

OREX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Orexigen Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. ValuEngine downgraded Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at

About Orexigen Therapeutics

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Insider Buying and Selling by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit